Jardiance May Slow Kidney Disease Development
New findings from last year’s study on the type 2 drug empagliflozin (Jardiance), which showed a benefit against heart disease, now reveal yet another advantage: The drug slows the development of kidney disease by 39 percent in people with type 2 diabetes at high risk for heart problems. About a third of people with diabetes develop some degree of kidney damage, so prevention is key. While metformin is still recommended as the first drug to treat type 2 diabetes, this new information may help doctors decide which drug to prescribe next for patients who need more help in achieving their glucose targets.
Source: The New England Journal of Medicine, published online June 14, 2016